We interpreted these results to mean that should gene expression in brain be associated with glioma risk, the same gene expression in blood cannot be assumed to also affect risk similarly; in some cases, the risk profile of genes expressed in brain and blood differed in direction of effect, e.g. STMN3 seems to increase risk when expressed in blood and decrease risk when expressed in brain. This evidence concerns the gene STMN3 and central nervous system cancer.